We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Treatment for Barret's Esophagus

By HospiMedica staff writers
Posted on 18 Jul 2002
A new therapy has been developed that shows promise for treating Barrett's esophagus, a precancerous condition caused by chronic, severe acid reflux. More...
Barrett's is difficult to diagnose and requires repeated endoscopic procedures coupled with random biopsies of suspect tissue. Moreover, Barrett's can progress to esophageal cancer, one of the deadliest forms of cancer. Numerous therapies are under investigation.

One new therapy uses a custom radio frequency (RF) generator and a single-use treatment catheter. The catheter is inserted endoscopically and positioned at the desired site. Then a short, controlled application of RF energy destroys the thin layer of precancerous cells, while the normal function of the muscular layer of the esophagus is preserved. The procedure is short, adding only an estimated 15 minutes to an endoscopy.

The new therapy was developed by Barrx Medical (West Monroe, LA, USA). The company believes the procedure will change the risk/benefit ratio in favor of early treatment of Barrett's, much as colonoscopy has changed the treatment of colon polyps, previously removed only by invasive surgery.

"Barrx Medical has developed a therapy with the safety, efficacy, and cost effectiveness to be routinely adopted by gastroenterologists for the treatment of Barrett's. We believe that none of the other therapies currently being investigated offer a workable solution,” said Roger Stern, Ph.D., a founder of Barrx and the president of Stellartech Research Corp. (Sunnyvale, CA, USA).



Related Links:
Stellartech Research Corp.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.